메뉴 건너뛰기




Volumn 7, Issue 3, 2012, Pages 219-225

Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab

Author keywords

age related macular degeneration; anti VEGF; monitoring; neovascularization; ranibizumab; treatment

Indexed keywords

AFLIBERCEPT; COMBRETASTATIN A4 PHOSPHATE; PROTEIN KINASE INHIBITOR; RANIBIZUMAB; SMALL INTERFERING RNA; VASCULOTROPIN INHIBITOR;

EID: 84861731047     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.12.24     Document Type: Review
Times cited : (6)

References (20)
  • 1
    • 13944266313 scopus 로고    scopus 로고
    • Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration
    • DOI 10.1167/iovs.04-0601
    • Gaudreault J, Fei D, Rusit J et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46, 726-733 (2005). (Pubitemid 40270359)
    • (2005) Investigative Ophthalmology and Visual Science , vol.46 , Issue.2 , pp. 726-733
    • Gaudreault, J.1    Fei, D.2    Rusit, J.3    Suboc, P.4    Shiu, V.5
  • 2
    • 33645331188 scopus 로고    scopus 로고
    • Tolerability and efficacy of multiple escalating doses of ranibizumab Lucentis) for neovascular age-related macular degeneration
    • Rosenfeld PJ, Heier JS, Hantsberger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 13(4), 623-632 (2006).
    • (2006) Ophthalmology , vol.13 , Issue.4 , pp. 623-632
    • Rosenfeld, P.J.1    Heier, J.S.2    Hantsberger, G.3    Shams, N.4
  • 3
    • 33645641520 scopus 로고    scopus 로고
    • Ranibizumab for treatment of neovascular age-related macular degeneration: A Phase I/II multicenter, controlled, multidose study
    • Heier JS, Antoszyk AN, Pavan PR et al. Ranibizumab for treatment of neovascular age-related macular degeneration: A Phase I/II multicenter, controlled, multidose study. Ophthalmology 113(4), 633-642 (2006).
    • (2006) Ophthalmology , vol.113 , Issue.4 , pp. 633-642
    • Heier, J.S.1    Antoszyk, A.N.2    Pavan, P.R.3
  • 6
    • 38349172455 scopus 로고    scopus 로고
    • Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
    • Regillo CD, Brown DM, Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am. J. Ophthalmol. 145, 239-248 (2008).
    • (2008) Am. J. Ophthalmol. , vol.145 , pp. 239-248
    • Regillo, C.D.1    Brown, D.M.2    Abraham, P.3
  • 7
    • 36448963442 scopus 로고    scopus 로고
    • The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization
    • DOI 10.1007/s00417-007-0638-x
    • Massacesi AL, Sacchi L, Bergamini F, Bottoni F. The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization. Graefe's Arch. Clin. Exp. Ophthalmol. 246, 89-92 (2008). (Pubitemid 350162687)
    • (2008) Graefe's Archive for Clinical and Experimental Ophthalmology , vol.246 , Issue.1 , pp. 89-92
    • Massacesi, A.L.1    Sacchi, L.2    Bergamini, F.3    Bottoni, F.4
  • 8
    • 74549137478 scopus 로고    scopus 로고
    • Ranibizumab (lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials
    • Mitchell P, Korobelnik JF, Lanzetta P et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials. Br. J. Ophthalmol. 94, 2-13 (2010).
    • (2010) Br. J. Ophthalmol. , vol.94 , pp. 2-13
    • Mitchell, P.1    Korobelnik, J.F.2    Lanzetta, P.3
  • 9
    • 57949094834 scopus 로고    scopus 로고
    • Ranibizumab versus Verteporfin photodynamic therapy for neovascular macular degeneration: Two-year results of the anchor study
    • Brown DM, Michels M, Kaiser PK et al. Ranibizumab versus Verteporfin photodynamic therapy for neovascular macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116, 57-65 (2009).
    • (2009) Ophthalmology , vol.116 , pp. 57-65
    • Brown, D.M.1    Michels, M.2    Kaiser, P.K.3
  • 10
    • 79955631484 scopus 로고    scopus 로고
    • Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study
    • Schmidt-Erfurth U, Eldem B, Guymer R et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study. Ophthalmology 118, 831-839 (2011).
    • (2011) Ophthalmology , vol.118 , pp. 831-839
    • Schmidt-Erfurth, U.1    Eldem, B.2    Guymer, R.3
  • 11
    • 77956056292 scopus 로고    scopus 로고
    • Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 2
    • Abraham P, Yue H, Wilson L et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 2. Am. J. Ophthalmol. 150, 315-324 (2010).
    • (2010) Am. J. Ophthalmol. , vol.150 , pp. 315-324
    • Abraham, P.1    Yue, H.2    Wilson, L.3
  • 12
    • 33947403618 scopus 로고    scopus 로고
    • An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration
    • Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol. 143, 566-583 (2007).
    • (2007) Am. J. Ophthalmol. , vol.143 , pp. 566-583
    • Fung, A.E.1    Lalwani, G.A.2    Rosenfeld, P.J.3
  • 13
    • 67149101784 scopus 로고    scopus 로고
    • A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study
    • Lalwani GA, Rosenfeld PJ, Fung AE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am. J. Ophthalmol. 148, 43-58 (2009).
    • (2009) Am. J. Ophthalmol. , vol.148 , pp. 43-58
    • Lalwani, G.A.1    Rosenfeld, P.J.2    Fung, A.E.3
  • 14
    • 79953295148 scopus 로고    scopus 로고
    • Safety and efficacy of flexible dosing regimen of ranibizumab in neovascular age-related degeneration: The SUSTAIN study
    • Holz FG, Amoaku W, Donate JD et al. Safety and efficacy of flexible dosing regimen of ranibizumab in neovascular age-related degeneration: The SUSTAIN study. Ophthalmology 118, 663-671 (2011).
    • (2011) Ophthalmology , vol.118 , pp. 663-671
    • Holz, F.G.1    Amoaku, W.2    Donate, J.D.3
  • 15
    • 36249002808 scopus 로고    scopus 로고
    • Ranibizumab for predominantly classic neovascular age-related macular degeneration: Sub-group analysis of first year ANCHOR results
    • Kaiser PK, Brown DM, Zhang K et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: Sub-group analysis of first year ANCHOR results. Am. J. Ophthalmol. 144, 850-857 (2007).
    • (2007) Am. J. Ophthalmol. , vol.144 , pp. 850-857
    • Kaiser, P.K.1    Brown, D.M.2    Zhang, K.3
  • 16
    • 33846586501 scopus 로고    scopus 로고
    • Sub-group analysis of the MARINA study of ranibizumab in neovascular age-related macula degeneration
    • DOI 10.1016/j.ophtha.2006.10.045, PII S0161642006014849
    • Boyer DS, Antoszyk AN, Awh CC et al. Sub-group analysis of the MARINA study of ranibizumab in neovascular age-related macula degeneration. Ophthalmology 114, 246-252 (2007). (Pubitemid 46172497)
    • (2007) Ophthalmology , vol.114 , Issue.2 , pp. 246-252
    • Boyer, D.S.1    Antoszyk, A.N.2    Awh, C.C.3    Bhisitkul, R.B.4    Shapiro, H.5    Acharya, N.R.6
  • 17
    • 34748844162 scopus 로고    scopus 로고
    • Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration
    • Kaiser PK, Blodi BA, Shapiro H et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114, 1868-1875 (2007).
    • (2007) Ophthalmology , vol.114 , pp. 1868-1875
    • Kaiser, P.K.1    Blodi, B.A.2    Shapiro, H.3
  • 18
    • 84984756571 scopus 로고    scopus 로고
    • The royal college of ophthalmologists interim recommendations for the management of patients with age-related macular degeneration
    • Amoaku WM. The royal college of ophthalmologists interim recommendations for the management of patients with age-related macular degeneration. Eye 22, 864-868 (2008).
    • (2008) Eye , vol.22 , pp. 864-868
    • Amoaku, W.M.1
  • 19
    • 70450201592 scopus 로고    scopus 로고
    • Ranbizumab: The clinician's guide to commencing, continuing, and discontinuing treatment
    • Amoaka WM. Ranbizumab: The clinician's guide to commencing, continuing, and discontinuing treatment. Eye 23, 2140-2142 (2009).
    • (2009) Eye , vol.23 , pp. 2140-2142
    • Amoaka, W.M.1
  • 20
    • 69249222585 scopus 로고    scopus 로고
    • A Phase III study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration
    • Boyer DS, Heier JS, Brown DM et al. A Phase III study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116(9), 1731-1739 (2009).
    • (2009) Ophthalmology , vol.116 , Issue.9 , pp. 1731-1739
    • Boyer, D.S.1    Heier, J.S.2    Brown, D.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.